Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oscient Pharmaceuticals Corp. (OSCI) -- Ignore unavailable to you. Want to Upgrade?

To: Glenn D. Rudolph who wrote (419)	6/30/1998 10:07:00 AM
From: Machaon	Read Replies (1) \| Respond to of 1154

I've got no info on the CSO leaving. But, I look back at Lehman's downgrade because of "lack of progress" back in January. And now, 6 months later, there is a flurry of activity and the CSO leaves. One could guess that he left because too much pressure was being put on him to produce more alliances. But, then again, they are not in a hurry to replace him. I wonder about why GENE doesn't seem to need another CSO. Their news release said that they weren't planning to replace him. Lehman said that two human genomic deals were possible in 1998. If this comes to be, the negative overhang of the PKN/TIGR project will disappear quickly. Sorry that I couldn't add more than a little conjecture. Perhaps someone else, on this very quiet thread, will have something more substantive. Good luck, Bob